Cannabis use is associated with lower retention in methadone maintenance treatment, but not among schizophrenic- and other chronically psychotic patients

The findings of studies on cannabis use and retention in methadone maintenance treatment (MMT) are inconsistent. To study cannabis use and its relationship to patients' outcomes in MMT with/without lifetime DSM-IV-TR schizophrenia/chronic-psychosis diagnosis. Since June 1993, 877 patients with...

Full description

Saved in:
Bibliographic Details
Published in:Journal of addictive diseases 2022-04, Vol.40 (2), p.183-191
Main Authors: Volkov, Ilan, Schreiber, Shaul, Adelson, Miriam, Shoshan, Stacy, Peles, Einat
Format: Article
Language:English
Subjects:
Cannabis
Cannabis - adverse effects
Diagnosis
Drug abuse
Drug screening
Drug use
Hallucinogens
Humans
Marijuana
Marijuana Abuse - complications
Marijuana Abuse - epidemiology
Medical diagnosis
Mental disorders
Mental Disorders - drug therapy
Methadone
Methadone - therapeutic use
methadone maintenance treatment
Opiate Substitution Treatment
Patients
Prospective studies
Psychosis
Psychotic Disorders - drug therapy
Retention
Schizophrenia
Schizophrenia - drug therapy
Schizophrenia - epidemiology
Schizophrenia/psychosis
Substance abuse treatment
Survival
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The findings of studies on cannabis use and retention in methadone maintenance treatment (MMT) are inconsistent. To study cannabis use and its relationship to patients' outcomes in MMT with/without lifetime DSM-IV-TR schizophrenia/chronic-psychosis diagnosis. Since June 1993, 877 patients with available lifetime DSM-IV-TR psychiatric diagnosis were followed-up until December 2017. Urine drug screens on admission and after one year were analyzed. Lifetime schizophrenia/psychosis was diagnosed in 50 (5.7%) patients. They did not differ from the other 827 by admission cannabis use (18.0% vs. 12.3%) and had similar 1-year retention rates (76.0% vs.77.0%, respectively). Cumulative retention of the cohort excluding schizophrenia/chronic-psychosis was longer for the 667 patients who did not use cannabis after 1-year (9.1 years, 95%CI 8.4-9.9) compared with the 118 cannabis-users after 1-year (6.0 years, 95% CI 4.8-7.2, p
ISSN:1055-0887
1545-0848
DOI:10.1080/10550887.2021.1962209